BiotechTube

Processed Nerve Allograft (human)

Phase 3Completed
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Peripheral Nerve Discontinuities

Conditions

Peripheral Nerve Discontinuities

Trial Timeline

Jun 1, 2015 → Aug 30, 2021

NCT ID
NCT01809002

About Processed Nerve Allograft (human)

Processed Nerve Allograft (human) is a phase 3 stage product being developed by Axogen for Peripheral Nerve Discontinuities. The current trial status is completed. This product is registered under clinical trial identifier NCT01809002. Target conditions include Peripheral Nerve Discontinuities.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01809002Phase 3Completed

Competing Products

20 competing products in Peripheral Nerve Discontinuities

See all competitors
ProductCompanyStageHype Score
SON-080Sonnet BioTherapeuticsPhase 1/2
36
LY3857210 + PlaceboEli LillyPhase 2
52
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
85
YHD1119 + LyricaYuhanPhase 1
33
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidYuhanApproved
85
YHD1119 + LyricaYuhanPhase 1
33
YHD1119 + LyricaYuhanPhase 3
77
YHD1119 300mg + YHD1119 300mgYuhanPhase 1
33
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsuleDaiichi SankyoPhase 2
52
edoxaban + Clopidogrel + AspirinDaiichi SankyoPhase 2
52
DS-5565 + placeboDaiichi SankyoPhase 3
77
Mirogabalin + PlaceboDaiichi SankyoPhase 3
77
DS-5565Daiichi SankyoPhase 3
77
Valemetostat TosylateDaiichi SankyoPhase 2
52
ASP3662 + pregabalin + ASP3662 placebo + pregabalin placeboAstellas PharmaPhase 2
52
QutenzaAstellas PharmaPre-clinical
23
QUTENZA + Lidocaine + TramadolAstellas PharmaApproved
85
Qutenza exposureAstellas PharmaPre-clinical
23
QUTENZAAstellas PharmaPhase 3
77
Qutenza + PregabalinAstellas PharmaApproved
85